Ask AI
ProCE Banner Activity

Moving Immunotherapy Into Earlier Settings for Triple-Negative Breast Cancer

Clinical Thought
Are you aware of the latest data on immune checkpoint inhibition for the treatment of early-stage TNBC? Read my thoughts on the promise of this strategy for our patients with this disease.

Released: April 17, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

Peter Schmid, MD, PhD, FRCP

Professor of Cancer Medicine
Centre Lead, Centre of Experimental Cancer Medicine
Director, Barts Breast Cancer Centre
London, United Kingdom

Peter Schmid, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, and Roche and funds for research support to his institution from Genentech, Novartis, OncoGenex, and Roche.